Profitability
Weight: 25%
C+
59
- 5yr Avg ROIC 6.4%
- Operating Margin Trend +27.74 pp/yr
ADMA
ADMA Biologics, Inc.
AlphaQuality composite grade, weighted for platform & compounding fcf businesses.
⚠ 3 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a platform & compounding fcf business.
Grade overrides the 30.0 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
D-
31
- 5yr Avg ROE 7.5%
- 5yr Share-Count CAGR 15.1%
Growth Quality
Weight: 25%
B-
65
- 5yr Revenue CAGR 58.4%
- 5yr EPS CAGR -25.9%
- Revenue-Growth Years (5) 5/5
Cash Generation
Weight: 20%
F
16
- 5yr FCF Margin -34.1%
- 5yr FCF/NI Conversion 0.37x
Balance Sheet
Weight: 10%
A+
98
- Net Debt / EBITDA -0.04x
- Interest Coverage (EBIT/Int) 26.69x
- Altman Z-Score 6.61
Stability
Weight: 5%
A
90
- EPS Volatility (σ/μ) 0.00
- Piotroski F-Score 6
- Negative-Revenue Years (5) 0/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.5 of 6 gurus held; 3 added; 2 trimmed; 1 full exit.
- Holders
- 5 -1
- Avg Δ position
- +117.9%
- New buys
- 0
- Full exits
- 1
- Greenblatt sold -100%
- Druckenmiller increased +513%
- Dalio increased +153%